[Lung Cancer with Pulmonary Embolism:
Evidence-based Progress in Anticoagulation Assessment and Management]

Lung cancer is the malignant tumour with the highest incidence and mortality rates globally. Patients with lung cancer face a high risk of developing venous thromboembolism (VTE), particularly pulmonary embolism (PE). This not only prolongs hospital stays and increases inpatient costs but also severely impacts patient survival and quality of life. Current risk assessment models for PE and bleeding risk in lung cancer patients remain limited in efficacy, posing challenges for clinicians in selecting anticoagulation or preventing bleeding. Additionally, anticoagulation management involves complex issues such as drug interactions and managing special populations. Based on existing literature, this review summarizes the clinical risk assessment and management of anticoagulation and bleeding, the selection of anticoagulants, and secondary prevention strategies for lung cancer patients with PE, to provide a reference for individualized clinical diagnosis and treatment.
.